Blog
About

5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Cost-effectiveness of full coverage of aromatase inhibitors for Medicare beneficiaries with early breast cancer.

      1 , , , ,

      Cancer

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Rates of nonadherence to aromatase inhibitors (AIs) among Medicare beneficiaries with hormone receptor-positive early breast cancer are high. Out-of-pocket drug costs appear to be an important contributor to this and may be addressed by eliminating copayments and other forms of patient cost sharing. The authors estimated the incremental cost-effectiveness of providing Medicare beneficiaries with full prescription coverage for AIs compared with usual prescription coverage under the Medicare Part D program.

          Related collections

          Author and article information

          Journal
          Cancer
          Cancer
          1097-0142
          0008-543X
          Jul 1 2013
          : 119
          : 13
          Affiliations
          [1 ] Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. kito@une.edu
          Article
          10.1002/cncr.28084
          23775433
          Copyright © 2013 American Cancer Society.

          Comments

          Comment on this article